Business Wire

CYT-0851 Phase 1 Dose Escalation Results Show Early Clinical Activity and Generally Well Tolerated Safety Profile in Advanced Solid Tumors and Hematologic Malignancies

- CYT-0851 has demonstrated broad clinical activity and a generally well tolerated safety profile in a heavily pretreated population of patients - Durable responses seen in both solid tumors and ...
Yahoo Finance

Cyteph Completes Recruitment for Phase I Clinical Trial of CYT-101 in Patients with Recurrent Glioblastoma Multiforme Brain Cancer

BRISBANE, Australia, Oct. 7, 2025 /PRNewswire/ -- Cyteph Pty Ltd, a biotechnology company developing novel immunotherapies for difficult-to-treat cancers, today announced that it has successfully ...
ascopubs.org

CPX-351 versus cytarabine (CYT) and daunorubicin (DNR) therapy in newly diagnosed AML patients age 60-75: Safety and efficacy in secondary AML (sAML).

Ponatinib in patients with acute myeloid leukemia (AML): Preliminary findings from a phase I study in hematologic malignancies. A phase III, open-label, randomized comparison of AS1413 (amonafide ...
Seeking Alpha

CYT Cyteir Therapeutics, Inc.

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits ...
Business Wire

Cyteir Therapeutics Announces Prioritization of CYT-0851 Development and Extended Cash Runway

- Encouraging early clinical results observed in treating ovarian cancer with CYT-0851 combination therapy - Strategic prioritization of clinical development of CYT-0851 combination therapy for ...